Simplify Logo

Full-Time

Sr. Director

Clinical Quality Assurance

Updated on 9/4/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Hardware
Biotechnology
Healthcare

Compensation Overview

$220k - $265kAnnually

+ Performance Bonus + Equity + Health Benefits

Senior, Expert

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor's degree in a scientific discipline or equivalent experience
  • Minimum of 8 years of experience in a GCP practice area; Clinical Quality Assurance or similar role preferred
  • Expertise with applicable GCP guidelines
Responsibilities
  • Identify opportunities for process improvement and lead initiatives to enhance efficiency, effectiveness, and compliance
  • Implement best practices and standardized processes to optimize quality assurance activities
  • Foster a culture of continuous improvement and innovation across the organization
  • Lead (or support) mock inspections, identify potential compliance gaps, and implement corrective actions as needed
  • Lead internal audits
  • Lead or support external audits, as deemed necessary
  • Review vendor, site and internal audit responses for adequacy and identify and propose relevant sponsor process improvement tasks/initiatives
  • Develop, review, and revise Standard Operating Procedures (SOPs) to ensure alignment with regulatory standards and industry best practices
  • Ensure SOPs are clear, comprehensive, and accessible to relevant stakeholders
  • Work closely with clinical study teams to ensure/coordinate appropriate documentation of quality event management, including corrective action and preventive action (CAPA) plans
  • Establish key quality metrics and performance indicators to monitor the effectiveness of clinical quality assurance activities
  • Analyze data trends, identify areas for improvement, and implement corrective and preventive actions to drive continuous quality improvement
  • Prepare comprehensive reports and presentations on quality assurance metrics and initiatives for senior management
  • Other duties as assigned or required

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Unlike many competitors, BridgeBio emphasizes independent thinking and transparency, enabling rapid, data-driven decision-making. The company's goal is to create significant therapeutic advancements by targeting diseases at their genetic source, ultimately bringing effective treatments to market more quickly.

Company Stage

IPO

Total Funding

$6.8B

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

53%

2 year growth

56%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.